{"filings":[{"id":91578,"accession_number":"0001628280-26-030896","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.","Licensed ARO-PNPLA3 from Arrowhead; clinical-stage siRNA targeting PNPLA3 mutation in MASH (≈30% of F2/F3 patients).","Net loss $94.4M ($3.25/share) vs $73.2M ($2.61) prior year; includes $54.3M one-time upfront BD expenses.","Cash $817.9M at Mar 31 (down from $988.6M Dec 31); MGL-2086 Phase 1 on track for Q2 2026.","Operating expenses $404.1M (incl $34M stock comp) vs $216.6M; SG&A up due to commercial investment."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":311337000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91577,"accession_number":"0001628280-26-027956","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal reclassifies two directors to balance board classes ahead of 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Julian C. Baker reclassified from Class III to Class I, term expiring at 2026 Annual Meeting.","Daniel J. Brennan reclassified from Class II to Class I, effective April 22, 2026.","Reclassification aims to achieve more equal apportionment among three board classes.","Baker, Brennan, and James Daly nominated for re-election at June 17, 2026 meeting.","No changes to committee assignments as a result of the reclassification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101771,"accession_number":"0001628280-26-009476","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.","More than 36,250 patients on Rezdiffra as of year-end 2025.","Cash, equivalents and marketable securities $988.6M as of Dec. 31, 2025.","Licensed global rights to six pre-clinical siRNA programs and oral GLP-1 (MGL-2086) to combine with Rezdiffra.","Secured Orange Book listed Rezdiffra patent with protection into 2045; also closed $500M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":958403000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101770,"accession_number":"0001104659-26-008698","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Madrigal gains full control over Rezdiffra patent term extensions from Roche","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.","Royalty reduction on Rezdiffra net sales is deferred until expiration of certain patent term extensions that have been or could be filed.","Amendment modifies the 2008 Research, Development, and Commercialization Agreement with Roche.","Madrigal also obtains full rights over joint patent rights and know-how without consent or accounting to Roche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118095,"accession_number":"0001628280-25-056533","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal appoints Rita Thakkar as SVP and Chief Accounting Officer, effective Jan 12, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rita Thakkar joins as principal accounting officer; Mardi Dier remains CFO and principal financial officer.","Thakkar previously SVP Global Business Operations at Bristol Myers Squibb and Chief Audit Officer at BMS and Celgene.","Annual base salary of $450,000 with target bonus of 40% of salary; initial equity grant valued at $1,932,000.","Equity award composed of 70% time-based RSUs (4-year vest) and 30% stock options (graded vest over 4 years).","Severance agreement provides 12 months salary and bonus upon qualifying separation, with enhanced benefits on change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118094,"accession_number":"0001628280-25-048525","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q3 2025 Rezdiffra sales $287.3M, annualizing >$1B; licenses oral GLP-1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rezdiffra net sales $287.3M in Q3 2025 vs $62.2M YoY; >29,500 patients on therapy.","Operating expenses $401.2M (R&D $174M incl upfront for CSPC, SG&A $209.1M).","Cash $1.1B; licensed global rights to oral GLP-1 (MGL-2086) from CSPC; clinic entry H1 2026.","New Orange Book patent for Rezdiffra covering weight-threshold dosing into 2045.","Launched Rezdiffra in Germany after EC conditional approval in August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":637320000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134542,"accession_number":"0001628280-25-037596","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.","New U.S. patent (No. 12,377,104) covers Rezdiffra weight-threshold dosing; expires Feb 4, 2045 (previously Sept 30, 2044).","Licensed global rights to oral GLP-1 candidate SYH2086 from CSPC Pharma; enters clinic H1 2026 for MASH combination.","Secured $500M senior secured credit facility with Blue Owl: $350M initial term loan, $150M delayed draw, plus up to $250M incremental.","Positive CHMP opinion for Rezdiffra in Europe; EC decision expected Aug 2025; would be first MASH therapy in EU."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":350052000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134541,"accession_number":"0001104659-25-071928","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Madrigal in-licenses oral GLP-1 SYH2086 from CSPC for up to $2B in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $120M; potential milestone payments up to $2B plus royalties on net sales.","Madrigal plans to start clinical development for SYH2086 in first half of 2026; deal expected to close Q4 2025.","Aims to combine Rezdiffra (resmetirom) with oral GLP-1 for MASH, citing enhanced antifibrotic benefit with modest weight loss.","CSPC retains rights to develop other oral GLP-1 agonists in China subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134540,"accession_number":"0001628280-25-035506","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Madrigal enters $500M credit facility with Blue Owl; $350M funded to repay debt and fund MASH pipeline","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$350M initial term loan funded at close; $150M delayed draw available through Dec 2027.","$121.6M used to repay existing Hercules Capital loan ($115M principal + fees), terminating that agreement.","Interest at base rate + 3.75% or Term SOFR + 4.75% (with 1% SOFR floor); maturity July 2030.","Uncommitted $250M incremental facility available by mutual consent for strategic expansion.","Covenant requires minimum $100M unrestricted cash at all times; secured by substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151388,"accession_number":"0001628280-25-032358","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Madrigal annual meeting results: directors re-elected, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected four Class III directors: Julian C. Baker, Raymond Cheong, Jacqualyn A. Fouse, Richard S. Levy — each with >17 million votes for.","Ratified appointment of PricewaterhouseCoopers as independent auditor for fiscal 2025 (20.2M for, 180K against).","Advisory say-on-pay approved (18.7M for) and frequency of one year adopted (18.9M for one-year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151387,"accession_number":"0001628280-25-021314","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.","Operating expenses $216.6M (up 42% YoY) driven by SG&A for Rezdiffra launch; R&D fell to $44.2M.","Cash, equivalents, restricted cash and marketable securities $848.1M at March 31, 2025.","Appointed David Soergel, M.D. as CMO; Jacqualyn Fouse, Ph.D. to Board of Directors.","Two-year F4c cirrhosis data from MAESTRO-NAFLD-1 accepted as EASL late-breaker (May 7–10)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":137250000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151386,"accession_number":"0001628280-25-018242","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal CMO/President of R&D Rebecca Taub steps down, becomes Senior Advisor through Dec 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Taub transitions from CMO and President of R&D to Senior Scientific and Medical Advisor effective April 21, 2025, through end of 2025.","She will continue to serve on Madrigal's Board of Directors.","Will receive base salary of $621,000 through Dec 31, 2025, and eligible for a 50% target bonus.","Entered a Severance and Change of Control Agreement with standard severance: 12-month salary continuation, equity acceleration, and health benefits.","No successor named; Taub will provide transition support and scientific guidance for MASH programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170277,"accession_number":"0001193125-25-051461","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Madrigal appoints Jackie Fouse to Board; Fred Craves to retire in July 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fred Craves, Ph.D. resigns from Madrigal's Board effective July 1, 2025; no disagreement cited.","Board expanded to 10 members; Jacqualyn Fouse, Ph.D. elected to fill new vacancy on March 10, 2025.","Fouse to serve on Audit and Nominating & Governance Committees; receives annual cash retainer of $50,000 plus committee fees.","Fouse granted $600,000 equity award (50% options, 50% RSUs) vesting over two years; prorated annual director award also granted.","Fouse is former CEO of Agios Pharmaceuticals and current Chair of Agios Board; over 30 years healthcare experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170276,"accession_number":"0001193125-25-035787","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.","Over 11,800 patients on Rezdiffra at year-end 2024; cash and marketable securities $931.3M.","Two-year open-label data in compensated MASH cirrhosis (F4c): mean 6.7 kPa liver stiffness reduction (VCTE), statistically significant vs baseline.","51% of F4c patients achieved ≥25% reduction in liver stiffness; safety profile consistent with prior trials.","MAESTRO-NASH OUTCOMES trial fully enrolled (data anticipated 2027); CHMP opinion expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-21.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":180133000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170275,"accession_number":"0001193125-25-004939","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports preliminary Rezdiffra Q4 2024 net sales $100M–$103M; over 11,800 patients on therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2024 Rezdiffra net sales $100M–$103M, full-year $177M–$180M.","Year-end cash, equivalents and marketable securities ~$931M.","Over 11,800 patients on Rezdiffra as of December 31, 2024.","EMA decision on Rezdiffra MAA expected mid-2025; German launch targeted H2 2025.","MAESTRO-NASH OUTCOMES trial in compensated cirrhosis fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187286,"accession_number":"0001193125-24-248137","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.","Cash, equivalents, and marketable securities $1.0B at Sep 30, 2024.","Operating expenses $178.5M vs $98.5M YoY; SG&A $107.6M driven by commercial launch.","Commercial coverage achieved for >80% of lives; <5% require biopsy for diagnosis.","Completed enrollment in MAESTRO-NASH OUTCOMES trial for compensated NASH cirrhosis; EMA decision mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-19.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":76813000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203788,"accession_number":"0001193125-24-195400","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.","Coverage in place for >50% of commercial lives; <5% of covered lives require biopsy.","EMA decision on resmetirom MAA expected mid-2025; plans to directly commercialize in Europe.","Q2 operating expenses $177.2M vs $86.5M YoY; SG&A drove increase on launch activities.","Cash, equivalents and marketable securities $1.1B vs $634.1M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":14638000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220376,"accession_number":"0001193125-24-170634","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Madrigal shareholders approve 750K share increase to stock plan, extend to 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2015 Stock Plan, increasing share reserve by 750,000 shares.","Plan extended through 2035; clawback policy and one-year minimum vesting requirement added.","All three Class II director nominees (Sibold, Taub, Craves) elected with over 95% support.","PricewaterhouseCoopers ratified as independent auditor for FY2024 with 99.4% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220375,"accession_number":"0001193125-24-133196","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Madrigal announces up to $300M ATM equity offering program with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered into Sales Agreement with TD Cowen to sell up to $300M of common stock via ATM.","Prior ATM program with Cowen terminated; had generated $225.1M from 1,333,594 shares.","Filed prospectus supplement registering up to 7,045,385 shares for selling stockholder; Madrigal receives no proceeds.","Sales may be made through TD Cowen as agent or principal; company not obligated to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220374,"accession_number":"0001193125-24-132559","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal posts Q1 net loss of ~$147.5M as Rezdiffra launch ramps up","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rezdiffra received FDA accelerated approval on March 14, 2024; first shipments to patients began in April.","No Q1 revenue; operating expenses of $152.0M (up 94% YoY) due to commercial preparation and headcount.","Cash, cash equivalents and marketable securities of $1.1B after $690M gross proceeds from public offering.","Appointed Mardi C. Dier as CFO on February 28, 2024.","European MAA for resmetirom validated and under EMA review."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220373,"accession_number":"0001193125-24-084797","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Madrigal raises ~$86M from underwriters' option exercise; total offering ~$660M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised option to purchase 346,153 shares at $260.00 per share.","Option exercise closed on April 2, 2024; net proceeds of ~$86 million.","Aggregate net proceeds from the offering and option exercise expected ~$660 million.","Offering included 750,000 shares and pre-funded warrants for 1,557,692 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240026,"accession_number":"0001193125-24-072706","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Madrigal raises ~$574M in public offering for Rezdiffra launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 750,000 shares at $260/share and 1,557,692 pre-funded warrants at $259.9999 each.","Net proceeds estimated at ~$574M; underwriters have 30-day option for up to 346,153 additional shares.","Proceeds to fund commercial launch of Rezdiffra (resmetirom) in the U.S. and for general corporate purposes.","Closing expected March 21, 2024; lock-up agreements for directors and officers for 60 days.","Underwriters include Goldman Sachs, Jefferies, Cowen, Evercore, Piper Sandler."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240025,"accession_number":"0001193125-24-068170","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Madrigal receives FDA accelerated approval for Rezdiffra, first NASH therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants accelerated approval for Rezdiffra in NASH with F2-F3 fibrosis; first approved therapy for NASH.","Approval based on Phase 3 MAESTRO-NASH: improved fibrosis and NASH resolution at 52 weeks vs placebo.","Prescribing info does not require liver biopsy; weight-based dosing (80mg <100kg, 100mg >=100kg).","Rezdiffra expected available in US in April via specialty pharmacy; patient support programs.","Most common adverse reactions: diarrhea, nausea, pruritus, abdominal pain. Continued approval contingent on confirmatory outcomes data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}